Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2022 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference

MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...
December 21, 2021 09:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21

NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
December 16, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

Helocyte, Inc., a partner company of Fortress Biotech, is developing Triplex for the treatment of cytomegalovirus Clinical trial will evaluate whether Triplex, which was developed by City of Hope,...
December 07, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease

NEW YORK and SOLANA BEACH, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from...
November 15, 2021 16:01 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights

Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record Journey Medical Corporation, a Fortress partner company, launched its $35.2 million initial...
October 18, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or...
October 08, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition

Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease Overall survival significantly improved in patients treated with CUTX-101 ...
October 06, 2021 08:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca

Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 NEW YORK and BORDENTOWN, N.J., Oct. 06, 2021 ...
October 05, 2021 08:30 ET | Source: Fortress Biotech, Inc.

Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer

NEW YORK and SCOTTSDALE, Ariz., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”) focused on...
September 29, 2021 07:00 ET | Source: Fortress Biotech, Inc.

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech

Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 AstraZeneca intends to advance and...